S -nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects

Bioconjugate Chemistry

Volumn 23, Issue 2, 2012, Pages 264-271

  Ishima, Yu ^a,b   Chen, Di ^a   Fang, Jun ^c   Maeda, Hiroshi ^c   Minomo, Ai ^a   Kragh Hansen, Ulrich ^d   Kai, Toshiya ^a,e   Maruyama, Toru ^a,b   Otagiri, Masaki ^a,c  

^a Department of Biopharmaceutics   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c SOJO UNIVERSITY   (Japan)

^d AARHUS UNIVERSITY   (Denmark)

^e Nipro Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM COMPOUNDS; BODY FLUIDS; CELL DEATH; CHEMICAL REACTIONS; CONTROLLED DRUG DELIVERY; MAMMALS; MONOMERS; NITRIC OXIDE; TARGETED DRUG DELIVERY; TUMORS;

AMINO-ACIDS; ANTI-CANCER THERAPEUTICS; ANTITUMOR DRUGS; DRUG-DELIVERY SYSTEMS; ENHANCED PERMEABILITY AND RETENTION EFFECT; HUMAN SERUM ALBUMINS; LOW MOLECULAR WEIGHT DRUGS; PHARMACOKINETIC PROFILES; THERAPEUTIC DRUGS; TUMOUR TISSUE;

DIMERS;

AMINO ACID; ANTINEOPLASTIC AGENT; DIMER; NITRIC OXIDE; RECOMBINANT HUMAN SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER TISSUE; CELL DEATH; COLON TUMOR; CONTROLLED STUDY; CYTOTOXICITY; DATA ANALYSIS; DRUG PENETRATION; DRUG RETENTION; IN VIVO STUDY; MALE; MEDICAL RECORD; MOUSE; NITROSATION; NONHUMAN; TUMOR CELL;

MURINAE; MUS;

EID: 84863147496     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc2005363     Document Type: Article

References (37)

1. Kerr, D. J. and Los, G. (1993) Pharmacokinetic principles of locoregional chemotherapy Cancer Surv. 17, 105-22
2. Reddy, L. H. (2005) Drug delivery to tumours: recent strategies J. Pharm. Pharmacol. 57, 1231-42 (Pubitemid 41545888)
3. Moses, M. A., Brem, H., and Langer, R. (2003) Advancing the field of drug delivery: taking aim at cancer Cancer Cell 4, 337-41 (Pubitemid 37491094)
4. Katayama, N., Nakajou, K., Komori, H., Uchida, K., Yokoe, J., Yasui, N., Yamamoto, H., Kai, T., Sato, M., Nakagawa, T., Takeya, M., Maruyama, T., and Otagiri, M. (2008) Design and evaluation of S -nitrosolated human serum albumin as novel anticancer drug J. Pharmacol. Exp. Ther. 325, 69-76 (Pubitemid 351439161)
5. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46, 6387-92 (Pubitemid 17221789)
6. Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210 (Pubitemid 20065994)
7. Maeda, H., Seymour, L. W., and Miyamoto, Y. (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo Bioconjugate Chem. 3, 351-62
8. Kiziltepe, T., Hideshima, T., Ishitsuka, K., Ocio, E. M., Raje, N., and Catley, L. (2007) JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells Blood 110, 709-18 (Pubitemid 47105410)
9. Ishima, Y., Yoshida, F., Kragh-Hansen, U., Watanabe, K., Katayama, N., Nakajou, K., Akaike, T., Kai, T., Maruyama, T., and Otagiri, M. (2011) Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin Free Radic. Res. 45, 1196-206
10. Yasuda, H. (2008) Solid tumor physiology and hypoxia-induced chemo/radio-resistence: Novel stragegy for cancer therapy: Nitric oxide donor as a therapeutic enhancer Nitric Oxide 19, 205-16
11. Yasuda, H., Yamaya, M., Kubo, H., and Sasaki, H. (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer J. Clin. Oncol. 24, 688-94 (Pubitemid 46630435)
12. Messmer, U. K., Reimer, D. M., and Brune, B. (1996) Nitric oxide-induced apoptosis: p53-dependent and p53-indeoendent signaling pathways Biochem. J. 319, 299-305 (Pubitemid 26394772)
13. Ulrich, C. M., Bigler, J., and Potter, J. D. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics Nat. Rev. Cancer 6, 130-40 (Pubitemid 43361545)
14. Hryniuk, W. A., Figueredo, A., and Goodyear, M. (1987) Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer Semin. Oncol. 11, 3-11 (Pubitemid 18035264)
15. Hogg, N. (2000) Biological chemistry and clinical potential of S-nitrosothiols Free Radic. Biol. Med. 28, 1478-86 (Pubitemid 30604230)
16. Wallace, J. L., Del, and Soldato, P. (2003) The therapeutic potential of NO-NSAIDs Fundam. Clin. Pharmacol. 17, 11-20 (Pubitemid 36241449)
17. Matsushita, S., Chuang, V. T., Kanazawa, M., Tanase, S., Kawai, K., Maruyama, T., Suenaga, A., and Otagiri, M. (2006) Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin Pharm. Res. 23, 882-91 (Pubitemid 43781396)
18. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 65, 271-84 (Pubitemid 30122932)
19. Tanaka, T., Shiramoto, S., Miyashita, M., Fujishima, Y., and Kaneo, Y. (2004) Tumor targeting based on the effect of enhanced permeability and retention and the mechanism of receptor-mediated endocytosis Int. J. Pharm. 227, 39-61 (Pubitemid 38670420)
20. Chen, R. F. (1967) Removal of fatty acids from serum albumin by charcoal treatment J. Biol. Chem. 242, 173-81
21. Ishima, Y., Sawa, T., Kragh-Hansen, U., Miyamoto, Y., Matsushita, S., Akaike, T., and Otagiri, M. (2007) S -nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties J. Pharmacol. Exp. Ther. 320, 969-77 (Pubitemid 46294047)
22. Sassa, H., Takaishi, Y., and Terada, H. (1990) The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria Biochem. Biophys. Res. Commun. 172, 890-7 (Pubitemid 20384507)
23. Akaike, T. (2000) Mechanisms of biological S -nitrosation and its measurement Free Radic. Res. 33, 461-9 (Pubitemid 32103688)
24. Yamasaki, Y., Sumimoto, K., Nishikawa, M., Yamashita, F., Yamaoka, K., Hashida, M., and Takakura, Y. (2002) Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors J. Pharmacol. Exp. Ther. 301, 467-77 (Pubitemid 34429956)
25. Peters, T., Jr. (1996) All about Albumin: Biochemistry, Genetics, and Medical Applications, Academic Press, San Diego.
26. Wu, J., Akaike, T., and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger Cancer Res. 58, 159-65 (Pubitemid 28027731)
27. Dreher, M., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., and Chilkoti, A. (2006) Tumor vascular permeability, Accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98, 335-44 (Pubitemid 43338213)
28. Jain, R. K. (2001) Delivery of molecular and cellular medicine to solid tumors Adv. Drug Delivery Rev. 46, 149-68
29. Sehouli, J., Stengel, D., Oskay, G., Camara, O., Hindenburg, H. J., Klare, P., Blohmer, J., Heinrich, G., Elling, D., Ledwon, P., Lichtenegger, W., and NOGGO study group (2002) A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy Ann. Oncol. 13, 1749-55 (Pubitemid 35439455)
30. Allen, T. M. and Cullis, P. R. (2004) Drug delivery systems: entering the mainstream Science 303, 1818-22 (Pubitemid 38374867)
31. Wosikowski, K., Biedermann, E., and Rattel, B. (2003) In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells Clin. Cancer Res. 9, 1917-26 (Pubitemid 36554620)
32. Burger, A. M., Hartung, G., Stehle, G., Sinn, H., and Fiebig, H. H. (2001) Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo Int. J. Cancer 92, 718-24 (Pubitemid 32385716)
33. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., and Damico, L. A. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins J. Biol. Chem. 38, 35035-43
34. Felix, K. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 132, 171-83
35. Bickel, U., Yoshikawa, T., and Pardridge, W. M. (2001) Delivery of peptides and proteinsthrough the blood-brain barrier Adv. Drug Delivery Rev. 46, 247-79
36. Lu, W., Sun, Q., Wan, J., She, Z., and Jiang, X. G. (2006) Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration Cancer Res. 66, 11878-87 (Pubitemid 46094200)
37. Seki, T., Fang, J., and Maeda, H. (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application Cancer Sci. 100, 2426-30